Press release: Uppsala, June 13, 2022. The company announces that members in the board and management are increasing their shareholding in the company.
Dicot is developing a new potency drug that aims to be the first choice for the treatment of erectile dysfunction and premature ejaculation.
The company announces today that members in the board and management are increasing their shareholding in the company. Purchase of shares, including exercise of warrants in the ongoing warrant round, series TO 3, means a total increase of holding for these members of board and management corresponding to approximately 700,000 shares.
For further information, please contact:
Elin Trampe, CEO
Tel: +46 739 80 14 08
Email: elin.trampe@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.